Current Report Filing (8-k)
March 16 2018 - 9:57AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): March 16,
2018
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36498
|
|
86-1032927
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(408)
973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation FD
Disclosure.
Attached as Exhibit
99.1 to this Current Report is the form of presentation that
Cellular Biomedicine Group, Inc. (the “Company”) used
in connection with the Company’s presentation on March 16,
2018 at the B. Riley FBR Inaugural China Healthcare Investing &
Partnering Symposium conference in Hangzhou, China, at which the
Company presented 48-week clinical data from its Phase I clinical
trial in China for allogeneic adipose-derived mesenchymal
progenitor cell off-the-shelf therapy Allojoin™ for Knee
Osteoarthritis.
On March 16, 2018, the Company issued a press
release announcing the presentation of the
Allojoin™
Phase I
48-week data in China, as well
as the termination of the Company’s U.S. Allojoin™
program with the California Institute of Regenerative Medicine
(“CIRM”). Prior to termination, the Company had
received $1.2 million of the potential $2.29 million available
under the CIRM grant. The press release is attached hereto as
Exhibit 99.2.
The
foregoing (including Exhibits 99.1 and 99.2) is being furnished
pursuant to Item 7.01 and will not be deemed to be filed for
purposes of Section 18 of the Securities and Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise be
subject to the liabilities of that section, nor will it be deemed
to be incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1
Presentation, dated March 16, 2018
99.2
Press
Release, dated March 16, 2018
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
Date:
March 16, 2018
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024